Although the RBD engages KRAS through a conserved mechanism, the BRAF(CRD) adopts a hinge-like displacement away from KRAS, forming fewer contacts and contributing less to binding than CRAF(CRD).
Abstract
SUMMARY MAPK pathway activation requires recruitment of RAF kinases by GTP-bound RAS through the RAS-binding domain (RBD) and cysteine-rich domain (CRD). BRAF uniquely contains an N-terminal BRAF-specific region (BSR), but the structural basis of KRAS engagement and BSR function remain unclear. Here, we report the structure of KRAS bound to BRAF(RBD-CRD) and compare it with KRAS-CRAF(RBD-CRD). Although the RBD engages KRAS through a conserved mechanism, the BRAF(CRD) adopts a hinge-like displacement away from KRAS, forming fewer contacts and contributing less to binding than CRAF(CRD). Structural analysis, biophysical measurements, and AlphaFold3 modeling show that the BSR does not directly contact KRAS but instead regulates RBD accessibility through a cis-acting mechanism that requires linkage to the RBD. Without the CRD, the BSR-RBD linker restricts KRAS binding, whereas CRD inclusion stabilizes BSR positioning and partially relieves inhibition. Disease-associated mutations further support a regulatory role for BRAF(CRD), defining an isoform-specific mechanism regulating RAF activation.
The RAS-RAF-MEK-ERK (MAPK) signaling cascade is a central regulator of cellular proliferation and differentiation, and its dysregulation is a frequent driver of oncogenesis. RAF activation requires recruitment by GTP-bound RAS at the plasma membrane; however, the precise molecular determinants governing RAS-RAF engagem...
Sravani Malasani, Zhi-Hong Wang· The FEBS Journal· 0 citations
It is demonstrated that KRAS is a central node in regulating growth factor-induced cell migration, and that KRAS inhibition plays a broader role than MAPK-mediated cell proliferation and survival.
Yang Yang, Ting-Yu Liu, Charles Y. Cho et al.· Oncogene· 0 citations
Daraxonrasib, which is an indirect inhibitor of wildtype and mutant H/K/NRAS isoforms, is FDA approved for the second-line treatment of all RAS-mutant pancreatic cancers.
R. Roskoski· Pharmacological Research· 0 citations
Upon RAS-driven membrane recruitment, RAF kinases ARAF, BRAF, and CRAF are activated through homo- or heterodimerization to initiate MAP kinase signaling. Although RAF heterodimers drive physiologic and oncogenic signaling, they remain little studied structurally and biochemically. Here, we report the preparation, bioc...
Byung Hak Ha, Emre Tkacik, D. Gazgalis et al.· Cell Reports· 1 citation
Results show that EGFR exon 19 mutations reshape the conformational landscape and local structural environment of the kinase, thereby influencing afatinib binding and the energetic environment of covalent bond formation.
Kousik K. Bhanja, Rajesh Ghosh, Niladri Patra· Journal of Physical Chemistr...· 1 citation
Direct targeting of KRAS through the Switch-II pocket is an effective therapeutic strategy, but acquired resistance limits clinical benefit. We examine clinically observed resistance mutations (R68S, H95Q, Y96C, Y96D and Q99L) arising during KRAS G12C inhibitor therapy using biochemical, structural, computational and c...
M. J. Whitley, M. Dyba, Mayukh Chakrabarti et al.· Nature Communications· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.